HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

B&L Pledges Commitment To Product Pipeline Despite R&D Cuts

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Bausch & Lomb remains dedicated to its R&D pipeline despite cutting its funding forecast for the remainder of the year, the company maintained during a third-quarter earnings call Oct. 19

You may also be interested in...



Pharma Firms Ready To Repatriate Billions Once “JOBS” Bill Is Signed

J&J intends to repatriate as much as $10 bil. held by foreign subsidiaries following President Bush's expected signing of the "JOBS" bill

Bausch & Lomb Looks To Vitamin Extension To Sustain Double-Digit Growth

Bausch & Lomb plans to launch a line extension and new formulation for its Ocuvite PreserVision vitamin brand this quarter

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

See All
UsernamePublicRestriction

Register

RS128398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By